Home JAK/STAT JAK inhibitor - IFN inhibitor Creatine

research use only

Creatine JAK inhibitor

Cat.No.S5588

Creatine (Methylguanidoacetic acid) is a nitrogenous organic acid that occurs naturally in vertebrates. It facilitates the recycling of adenosine triphosphate (ATP) primarily in muscle and brain tissue. This compound can inhibit the JAK-STAT1 signal transmission by inhibiting the interaction of IFN-γ receptors with JAK2 in an ATP-independent manner, thereby inhibiting downstream pro-inflammatory gene expression.
Creatine JAK inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 131.13

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: S558801 Water]18 mg/mL]true]DMSO]Insoluble]false]]]false Purity: 98%
98

Chemical Information, Storage & Stability

Molecular Weight 131.13 Formula

C4H9N3O2

 Storage (From the date of receipt) 3 years -20°C powder
CAS No. 57-00-1 -- Storage of Stock Solutions

Synonyms Methylguanidoacetic acid Smiles CN(CC(=O)O)C(=N)N

Solubility

In vitro
Batch:

Water : 18 mg/mL (超声加热十分钟，60℃)

DMSO : Insoluble
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
JAK2 [1]
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04218786 Withdrawn
Myocardium; Injury|Myocardial Infarction|Myocardial Ischemia
Shifa Tameer-e-Millat University|Rawalpindi Institute of Cardiology
 December 2025 Phase 2
NCT06225570 Not yet recruiting
Acne Vulgaris
Medical University of South Carolina
 January 2025 Early Phase 1
NCT05627479 Not yet recruiting
Femoral Shaft Fracture|Tibial Shaft Fracture
NYU Langone Health
 December 1 2024 Phase 2
NCT05647811 Not yet recruiting
C3 Glomerulopathy
NovelMed Therapeutics
 November 2024 Phase 1|Phase 2
NCT05946772 Not yet recruiting
Takotsubo Cardiomyopathy
University Hospital Heidelberg|German Centre of Cardiovascular Research (DZHK)|Coordinating Centre for Clinical Studies (KKS) Heidelberg
 October 2024 Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map